Document Detail


Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
MedLine Citation:
PMID:  22285697     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Prostate cancer is the most prevalent urogenital malignancy. However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that is resistant to further hormone manipulation. For these patients with castration-resistant prostate cancer (CRPC), and particularly patients with metastatic disease, options have been limited, and prognosis is grim. However, as newer regimens and agents become available, higher rates of objective and biochemical response are being achieved, providing renewed hope for the management of these patients. With the aim of facilitating the treatment of these patients, the Spanish Oncology Genitourinary Group (SOGUG) has issued a series of the recommendations which have been collected in this review. Each recommendation is accompanied by the appropriate level of evidence and grade of recommendation on the basis of the characteristics of the data available.
Authors:
Miguel A Climent; Josep María Piulats; Alfredo Sánchez-Hernández; José Ángel Arranz; Javier Cassinello; Jesús García-Donas; Aránzazu González del Alba; Luis León-Mateos; Begoña Mellado; María José Méndez-Vidal; Begoña Pérez-Valderrama;
Related Documents :
23935937 - Structural and logical analysis of a comprehensive hedgehog signaling pathway to identi...
12384747 - A biological approach to treating disc degeneration: not for today, but maybe for tomor...
22846487 - Penile cancer.
18287767 - Tissue sample collection for proteomics analysis.
19610267 - Hypersensitivity pneumonitis following intravesical bacille calmette-guérin immunothera...
20427357 - Population-based cancer registries in spain and their role in cancer control.
Publication Detail:
Type:  Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't     Date:  2012-01-29
Journal Detail:
Title:  Critical reviews in oncology/hematology     Volume:  83     ISSN:  1879-0461     ISO Abbreviation:  Crit. Rev. Oncol. Hematol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-13     Completed Date:  2012-12-19     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8916049     Medline TA:  Crit Rev Oncol Hematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  341-52     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Instituto Valenciano de Oncología (IVO), Valencia, Spain. macliment@fivo.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androgen Antagonists / therapeutic use
Antineoplastic Agents, Hormonal / therapeutic use
Bone Neoplasms / secondary,  therapy
Gonadotropin-Releasing Hormone / analogs & derivatives,  therapeutic use
Humans
Male
Neoplasm Metastasis
Orchiectomy*
Prostatic Neoplasms / pathology*,  therapy*
Radiation-Sensitizing Agents / therapeutic use
Taxoids / therapeutic use
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Antineoplastic Agents, Hormonal; 0/Radiation-Sensitizing Agents; 0/Taxoids; 15H5577CQD/docetaxel; 33515-09-2/Gonadotropin-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in ...
Next Document:  Optimization of DNA-directed immobilization on mixed oligo(ethylene glycol) monolayers for immunodet...